Evidence map›Paper›PMID 31706351›Full record

ArticleActa neuropathologica communications2019

The level of activity of the alternative lengthening of telomeres correlates with patient age in IDH-mutant ATRX-loss-of-expression anaplastic astrocytomas.

Nathalie Grandin, Bruno Pereira, Camille Cohen, Pauline Billard, Caroline Dehais, Catherine Carpentier, Ahmed Idbaih, Franck Bielle, François Ducray, Dominique Figarella-Branger and 7 more

Open access · goldAbstract read
In one paragraph

Article in Acta neuropathologica communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. TERT expression increases with tumor grade in a cohort ofAmerican journal of translational research · 2022
    Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Nathalie GrandinLaboratoire GReD, CNRS UMR6293, INSERM U1103, Faculty of Medicine, Bldg CRBC, 2nd floor, 28 place Henri Dunant, 63001, Clermont-Ferrand, France.
Bruno PereiraCHU Clermont-Ferrand, Biostatistics unit, DRCI, 63003, Clermont-Ferrand, France.
Camille CohenUniversité de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5310, INSERM U 1217, LabEx DEVweCAN, Institut NeuroMyoGène (INMG), Lyon, France.
Pauline BillardUniversité de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.
Caroline DehaisAP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de neurologie 2-Mazarin, 75013, Paris, France.
Catherine CarpentierSorbonne Université, INSERM, CNRS, UMR S1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.
Ahmed IdbaihAP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de neurologie 2-Mazarin, 75013, Paris, France.
Franck BielleSorbonne Université, INSERM, CNRS, UMR S1127, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France.
François DucrayHospices Civils de Lyon, Hôpital Pierre Wertheimer, Service de Neuro-oncologie, Bron, France.
Dominique Figarella-BrangerAPHM, Hôpital de la Timone, Service d'Anatomie Pathologique et de Neuropathologie, Marseille, France.
Jean-Yves DelattreAP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de neurologie 2-Mazarin, 75013, Paris, France.
Marc SansonAP-HP, Groupe Hospitalier Pitié-Salpêtrière Charles Foix, Service de neurologie 2-Mazarin, 75013, Paris, France.
Patrick LomonteUniversité de Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5310, INSERM U 1217, LabEx DEVweCAN, Institut NeuroMyoGène (INMG), Lyon, France.
Delphine PoncetUniversité de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Centre de recherche en cancérologie de Lyon, Lyon, France.
Pierre VerrelleUniversité Clermont Auvergne, 63001, Clermont-Ferrand, France. pierre.verrelle@clermont.unicancer.fr.
Michel CharbonneauLaboratoire GReD, CNRS UMR6293, INSERM U1103, Faculty of Medicine, Bldg CRBC, 2nd floor, 28 place Henri Dunant, 63001, Clermont-Ferrand, France. michel.charbonneau@uca.fr.ORCID 0000-0002-6684-6151
POLA network
Centre National de la Recherche Scientifique · FRUniversité Claude Bernard Lyon 1 · FR

Funding

Canceropôle Lyon Auvergne Rhone-Alpes (FR) OncostarterFondation ARC pour la Recherche sur le Cancer subvention fixeInstitut National Du Cancer POLA networkLabex DEVweCANLigue Contre le Cancer Grand Ouest
6 · The paper itself

Abstract

All cancer cells need to maintain functional telomeres to sustain continuous cell division and proliferation. In human diffuse gliomas, functional telomeres are maintained due either to reactivation of telomerase expression, the main pathway in most cancer types, or to activation of a mechanism called the alternative lengthening of telomeres (ALT). The presence of IDH1/2 mutations (IDH-mutant) together with loss of ATRX expression (ATRX-lost) are frequently associated with ALT in diffuse gliomas. However, detection of ALT, and a fortiori its quantification, are rarely, if ever, measured in neuropathology laboratories. We measured the level of ALT activity using the previously described quantitative "C-circle" assay and analyzed it in a well characterized cohort of 104 IDH-mutant and ATRX-lost adult diffuse gliomas. We report that in IDH-mutant ATRX-lost anaplastic astrocytomas, the intensity of ALT was inversely correlated with age (p < 0.001), the younger the patient, the higher the intensity of ALT. Strikingly, glioblastomas having progressed from anaplastic astrocytomas did not exhibit this correlation. ALT activity level in the tumor did not depend on telomere length in healthy tissue cells from the same patient. In summary, we have uncovered the existence, in anaplastic astrocytomas but not in glioblastomas with the same IDH and ATRX mutations, of a correlation between patient age and the level of activity of ALT, a telomerase-independent pathway of telomere maintenance.

Indexed as

AdultAgedAstrocytomaBrain NeoplasmsCohort StudiesFemaleGene Expression Regulation, NeoplasticHumansIsocitrate DehydrogenaseMaleMiddle AgedMutationTelomere HomeostasisX-linked Nuclear ProteinATRX protein, humanIDH1 protein, humanIDH2 protein, humanIsocitrate DehydrogenaseX-linked Nuclear ProteinAlternative lengthening of telomeresAnaplastic astrocytomaATRX loss of expressionIDH1/2 mutationsSecondary glioblastoma

Identifiers

PMID31706351
PMCPMC6842523
OpenAlexW2987817017

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.